Spark signs gene therapy licensing deal valued at up to $328.5M
Philadelphia gene therapy pioneer Spark Therapeutics signed a collaboration and licensing agreement Tuesday that gives its exclusive rights to further develop and commercialize a Swedish company's experimental focal epilepsy treatment.
Under the terms of agreement, Spark, of division of Roche, will pay CombiGene up to $328.5 million plus royalties for the rights to its CG01 gene therapy project.
The deal includes $8.5 million upfront and $50 million when certain preclinical and clinical milestones…
Source: bizjournals.com Health Care:Pharmaceuticals headlines - Category: Pharmaceuticals Authors: John George Source Type: news